FIELD: medicine.
SUBSTANCE: invention refers to medicine, and concerns a method of body weight reduction, diabetes treatment, HbAlC level decrease or plasma glucose level decrease on an empty stomach by the use of exendin or an exendin agonist analogue.
EFFECT: invention provides a specific plasma level (170 pg/ml to 290 pg/ml) of exendin or its agonist analogue for at least 1 month.
19 cl, 1 ex, 3 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| METHOD OF GLP-1 MOLECULES INTRODUCTION | 2003 |
|
RU2332229C2 |
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
| COMPOSITION AND MICROSPHERE WITH CONTROLLED EXENDIN RELEASE AND METHOD OF OBTAINING MICROSPHERE | 2008 |
|
RU2463040C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| GLP-2 PEPTIBODY FOR INTRODUCTION BEFORE, DURING OR AFTER SURGICAL INTERVENTION | 2018 |
|
RU2795594C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
